In NSCLC treatment, antiangiogenic agents, tyrosine kinase inhibitors (TKIs) for EGFR-mutant or anaplastic lymphoma kinase (ALK) rearrangement patients have significantly improved the clinical prognosis.275,276 Antiangiogenic agents, for instance bevacizumab combinded with ICB can improve the theraperutic efficacy at the same time.277,278 However, the combination of TKI and ICB is not promising because of higher risk of irAEs and none significant clinical benefits.279 It may be a good choice to use ICB after TKI resistance in these patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.